Effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size

被引:36
作者
Kesler, A
Shemesh, G
Rothkoff, L
Lazar, M
机构
[1] Tel Aviv Univ, Tel Aviv Med Ctr, Sackler Sch Med, Dept Ophthalmol, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Univ, Tel Aviv Med Ctr, Sackler Sch Med, Neuroophthalmol Unit, IL-64239 Tel Aviv, Israel
[3] Ophthalm Hlth Ctr, Tel Aviv, Israel
关键词
D O I
10.1016/j.jcrs.2004.02.043
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To evaluate the effect of brimonidine tartrate 0.2% ophthalmic solution on pupil size under scotopic and photopic luminance conditions in persons considering laser refractive surgery. Setting. Ophthalmic Health Center, Tel Aviv, Israel. Methods: The pupil size was measured in 36 eyes of 36 participants under scotopic and photopic conditions using the Colvard pupillometer (Oasis Medical) before and after brimonidine tartrate drops were administered. The pupil size was subsequently measured after 30 minutes and 4 and 6 hours. Results: No difference was found in pupil size before brimonidine tartrate instillation in eyes with light or dark irides. Before instillation, the mean photopic pupil size was 4.81 mm +/- 0.54 (SD) (range 4.0 to 6.0 mm). At 30 minutes, all pupils became miotic, with a mean size of 3.77 +/- 0.51 mm (range 3.0 to 5.0 mm) (P<.0001). After 6 hours, 27.8% of the pupils had returned to their previous size. Before brimonidine tartrate administration, the mean scotopic pupil size was 6.22 +/- 0.73 mm (range 5.0 to 8.0 mm). There was significant miosis to 4.57 +/- 0.84 mm (range 3.0 to 6.5 mm) (P<.0001) that continued for at least 6 hours. The miotic effect of brimonidine tartrate was stronger in eyes with light irides. Conclusions: Brimonidine tartrate caused significant miosis, especially under scotopic conditions, most likely from its alpha-2 adrenergic effect. Under photopic luminance conditions, the miotic effect was pronounced. (C) 2004 ASCRS and ESCRS.
引用
收藏
页码:1707 / 1710
页数:4
相关论文
共 8 条
[1]   The influence of iris color on the pupillary light reflex [J].
Bergamin, O ;
Schoetzau, A ;
Sugimoto, K ;
Zulauf, M .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1998, 236 (08) :567-570
[2]   Brimonidine tartrate - A one-month dose response study [J].
Derick, RJ ;
Robin, AL ;
Walters, TR ;
Barnebey, HS ;
Choplin, N ;
Schuman, J ;
Kelley, EP ;
Chen, KK ;
Stoecker, JF .
OPHTHALMOLOGY, 1997, 104 (01) :131-136
[3]   Night vision disturbances after corneal refractive surgery [J].
Fan-Paul, NI ;
Li, J ;
Miller, JS ;
Florakis, GJ .
SURVEY OF OPHTHALMOLOGY, 2002, 47 (06) :533-546
[4]   Effects of 0.2% brimonidine on ocular anterior structures [J].
Marchini, G ;
Babighian, S ;
Tosi, R ;
Bonomi, L .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 1999, 15 (04) :337-344
[5]  
Mastropasqua L, 1998, OPHTHALMOLOGY, V105, P1352, DOI 10.1016/S0161-6420(98)98006-X
[6]   Effect of brimonidine tartrate ophthalmic solution 0.2% on pupil size in normal eyes under different luminance conditions [J].
McDonald, JE ;
Kotb, AME ;
Decker, BB .
JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2001, 27 (04) :560-564
[7]  
Norden RA, 2002, J REFRACT SURG, V18, P468
[8]   THE CARDIOVASCULAR, PULMONARY, AND OCULAR HYPOTENSIVE EFFECTS OF 0.2-PERCENT BRIMONIDINE [J].
NORDLUND, JR ;
PASQUALE, LR ;
ROBIN, AL ;
RUDIKOFF, MT ;
ORDMAN, J ;
CHEN, KS ;
WALT, J .
ARCHIVES OF OPHTHALMOLOGY, 1995, 113 (01) :77-83